Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.
about
Fifty years of melphalan use in hematopoietic stem cell transplantationUpdate on treatment of light chain amyloidosisImproved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyNanoliposomes protect against AL amyloid light chain protein-induced endothelial injuryAn overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow upCardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failurePOEMS syndrome: 2014 update on diagnosis, risk-stratification, and management.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.POEMS syndrome: update on diagnosis, risk-stratification, and management.POEMS syndrome: 2017 Update on diagnosis, risk stratification, and management.Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patientsSuccessful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?Autologous stem cell transplantation and IgM amyloidosis.Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.Perspectives in treatment of AL amyloidosis.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chainPOEMS syndrome: 2011 update on diagnosis, risk-stratification, and management.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.Future directions in the clinical management of amyloid light-chain amyloidosis.Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.Emerging Advances in the Management of Cardiac Amyloidosis.New and developing therapies for AL amyloidosis.Heart transplantation in cardiac amyloidosis.High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.18F-fluorodeoxyglucose positron emission tomography might be useful for diagnosis of hepatic amyloidosis.Vertebra collapse due to primary amyloidosis causing neurological compromise.Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis.Autologous stem cell transplant for Al amyloidosis.Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients.Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
P2860
Q26824498-7C2FD336-BC12-4A2F-AB14-1FB93673712BQ26829735-5E9AD0DE-AF8F-43B6-9772-FF04C0AAC450Q30278687-47726DF4-AFEB-45AB-BC78-3AE996599719Q30355633-1D897EC4-A337-4C0C-ADD2-BB23FB490088Q33304297-03B3C2EC-07B3-4B55-B080-F572F656F3DDQ33439299-64833BD0-E38B-4A9C-9894-4C97C2B9E087Q34240595-D1E0D75D-328B-472B-B02E-B348E854A5CBQ34404620-BEED38CB-2461-4178-8EE7-E01490ACEC2AQ34450910-B927CE19-651F-4A78-AFF7-5E7CAE878ECAQ34482518-4792453E-D9CD-4E83-BEFC-27A14ED8B37FQ34492003-2034BA57-375D-4D61-8039-9A3E34834669Q34558653-859EEC34-F99B-44DB-833A-7B18E80BB625Q35208216-1AA15EDD-0B00-4D6A-A570-D395EB14F1F7Q35485742-2FF48BD3-D33A-4D03-BFBF-CBD94C12267FQ35848844-24A84FCD-2858-4ABC-A583-43EEBC15E4E8Q36215543-9AAC1024-8E30-44E6-B958-FE3F6377E25FQ36301287-FB9031BD-69F4-41AC-8360-AA6BE9AB6E69Q36484561-0295FD09-98A5-40AC-83B7-E1157C0EAFBDQ36535491-C2D4A4FF-812C-4CFA-BA69-3F740EEC3739Q36779777-6A68C8D1-4825-4F4E-9035-5EEAA6E793F0Q37045885-C1FBE640-506E-461E-B56F-BE511C95011EQ37045900-FDABCD5D-AE78-4916-9E04-AAFC57C36C41Q37059137-4AFE9F07-CF9E-4FBD-AD8A-7058F4D0B6E9Q37284404-EFD7FDCC-9F91-477C-BDD4-B2EAE9FC2E73Q37890982-3D3E4DB5-82B4-40B9-B84E-F58A68841110Q37904673-5CDB4613-3A8B-47F7-9FF9-66C1D548BD2EQ37995198-28A92BEE-C24B-4C9D-8DBA-D3FF6D4FA666Q38172998-8A4F4E8B-9EEB-429B-9FA3-E87095C29C93Q38370866-936FF7DC-1DBA-4A82-8CC3-E021FB42FE64Q38587648-81A5913C-C51C-4422-98C0-E2F4CC7C6F58Q38779623-716436A7-EC1B-4621-BEE7-9EF105DCE14EQ39172346-D8421BA7-3C69-4E79-9749-107944DBD73BQ41021929-77CBD7CA-A872-44EA-BC7B-BEF0D2F0D617Q41428960-49601A39-3F24-45CB-A038-E052B0AE964DQ41822878-15C29824-7A86-46E9-B5BC-95108DC16EFFQ41937030-B1084D29-15DF-4004-A9E5-BD812CB26C01Q42179759-366428EE-7A11-4E74-83A5-49CB59039516Q42879120-4B7B618B-A9C0-4A23-931F-C579C9D81ABCQ43583135-AE64A125-394E-4952-80D9-3CC5000AAB47Q43936667-0A718069-C23B-4653-972D-645858528165
P2860
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Superior survival in primary s ...... ntation: a case-control study.
@en
Superior survival in primary s ...... ntation: a case-control study.
@nl
type
label
Superior survival in primary s ...... ntation: a case-control study.
@en
Superior survival in primary s ...... ntation: a case-control study.
@nl
prefLabel
Superior survival in primary s ...... ntation: a case-control study.
@en
Superior survival in primary s ...... ntation: a case-control study.
@nl
P2093
P50
P1433
P1476
Superior survival in primary s ...... ntation: a case-control study.
@en
P2093
David J Inwards
Denise S Snow
Dennis A Gastineau
Dirk R Larson
Ivana N Micallef
John A Lust
Luis F Porrata
Mark R Litzow
Matthew F Plevak
Michelle A Elliott
P304
P356
10.1182/BLOOD-2003-12-4192
P407
P50
P577
2004-01-22T00:00:00Z